ORBIO CORPORATION | Oncotherapy Revolution by L-Glucose

Oncotherapy Revolution
By Isomer Organics

ABOUT

Delivering a therapeutic drug for intractable cancer to society with L-glucose, which is highly selective for cancer cells.

We are a medical startup company founded in Kyoto in 2018 with the goal of bringing a therapeutic drug for intractable cancer to society. We are researching cancer treatment technologies and creating cancer diagnostic and therapeutic drugs so that we can help patients suffering from cancer as soon as possible.

CORPORATE

MISSION

Leading patients with intractable cancer to a complete cure.

We aim to realize a new anti-cancer drug with L-glucose bound Orbio-molecules. We deliver the hope of complete cure beyond the diversity of intractable cancer.
Introducing a new treatment modality for cancer therapy.

We will implement “cancer-specific cell therapy” using L-glucose as a drug delivery system (DDS), which shows unprecedented high selectivity in cancer treatment.

TECHNOLOGY

VALUE

TEAM

KEI
YAMAGUCHI
CEO

Master of Commerce
Dr. KATSUYA
YAMADA
CSO

Professor, Specially-appointed,
Department of Molecular Transport (Hirosaki University-ORBIO Joint Research Course)
National University Corporation Hirosaki University Graduate School of Medicine

Visiting Professor
Department of Hepatobiliary-Pancreatic Surgery
Osaka Metropolitan University Graduate School of Medicine

Ph.D. in Medicine
Dr. EIICHI
YAMAGUCHI
CVO

Professor Emeritus, Kyoto University

Doctor of Science
Dr. HIDEKI
IIJIMA
COO

Doctor of Engineering

Ph.D. in Management of Innovative Management